NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake

NEXGEL, INC.

NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.
NEXGEL will receive a 5% global royalty in perpetuity on products sold using its drug delivery technology.
NexGelRx closed initial funding from outside investors; NEXGEL will be exclusive manufacturer of hydrogel for NexGelRx.
Dr. Jerome Zeldis, NEXGEL director who helped bring 10 pharma products to market, will also serve on NexGelRx board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.